Related Experiment Video
Updated: Aug 19, 2026

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 21, 2014
Prostanoids and cyclic nucleotides in malignant and benign ovarian tumors
1Department of Obstetrics and Gynecology, University Central Hospital, Tampere, Finland.
Abstract:
The concentrations of prostaglandin E2 (PGE2), 6-keto-PGF1 alpha, thromboxane B2(TxB2), cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in ovarian tumor tissue were measured in 38 post-menopausal women with malignant or benign ovarian tumor and in six women without ovarian neoplasm. PGE2 and TxB2 contents in ovarian cancer tissue were significantly (P less than 0.05) higher than in normal ovarian tissue. The prostanoids were also increased in the cyst fluid of epithelial malignant tumors compared to cyst fluids of benign ovarian tumors. Cyclic AMP concentrations in cancer tissue were lower than in non-malignant ovarian tissue, while the levels of cGMP were similar in all groups studied.
Related Concept Videos
Oogenesis
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Ovarian Cycle
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

